Status:
COMPLETED
APERIO® HYBRID Thrombectomy Device for Flow Restoration in Vessels of Patients Experiencing Acute Ischemic Stroke
Lead Sponsor:
Acandis GmbH
Conditions:
Acute Stroke
Eligibility:
All Genders
18+ years
Brief Summary
This is a prospective, multicenter, single-arm, open-label, national Post-Market Clinical Follow-up study to collect comprehensive information on technical and clinical success and safety of the use o...
Detailed Description
German APERIO® Hybrid Post- Market Clinical Follow-up Study APERIO® Hybrid PMCF Study- Thrombectomy device for flow restoration in vessels of patients experiencing acute ischemic stroke Study Type: ...
Eligibility Criteria
Inclusion
- \- All patients treated with APERIO® HYBRID and/or APERIO® Hybrid(17/21) Thrombectomy Device as a result of an acute stroke.
Exclusion
- Patient age \< 18 years
- Pre stroke mRS ≥ 3
Key Trial Info
Start Date :
November 2 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2023
Estimated Enrollment :
190 Patients enrolled
Trial Details
Trial ID
NCT04457479
Start Date
November 2 2020
End Date
June 30 2023
Last Update
August 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Evangelisches Krankenhaus Oldenburg
Oldenburg, Germany, 26122